文献速递急性肾损伤遗传性与小管间质肾病血液净化与透析

卡非佐米相关血栓性微血管病的临床特征与结局

Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

该研究基于法国TMA参考中心登记的37例卡非佐米相关血栓性微血管病(CFZ-TMA)病例,分析其临床特征、遗传背景及治疗结局。所有患者均出现急性肾损伤(84%为KDIGO 3期),94%的TMA缓解但44%出院时仍为3期AKI;补体旁路途径变异及补体阻断治疗未显示与疾病病理生理或预后相关。

要点

  • CFZ-TMA以严重急性肾损伤为突出表现,84%达KDIGO 3期。
  • 多数患者TMA缓解,但44%出院时仍遗留3期AKI。
  • 血浆置换、糖皮质激素或依库珠单抗均未显示显著影响结局。

核心结论

  • CFZ-TMA患者表现为严重AKI且常遗留后遗症,补体变异与补体阻断治疗似乎不参与疾病病理生理及预后。

研究设计与样本

  • 法国TMA参考中心登记的37例卡非佐米相关TMA病例系列,收集临床特征、遗传分析及按治疗分组结局。

主要发现

  • 超过半数病例存在触发因素,包括8例流感和5例SARS-CoV-2感染。
  • 所有患者均出现AKI,KDIGO 3期31例(84%),神经系统损害13例(36%),心脏损害7例(19%)。
  • ADAMTS13和补体活性正常(分别检测28例和18例),7例检测患者中未发现补体旁路途径致病性变异。
  • TMA缓解34例(94%),但出院时仍为3期AKI者12例(44%)。
  • 19例(51%)接受治疗性血浆置换,14例(38%)接受糖皮质激素,18例(50%)接受依库珠单抗,均未显示对结局有显著影响。

关键数值与推荐

  • AKI分期采用KDIGO标准,3期31例(84%)。
  • TMA缓解定义为TMA缓解,34例(94%)达到。
  • 出院时3期AKI遗留12例(44%)。

临床怎么用

  • 对卡非佐米治疗患者应监测肾功能与TMA征象,警惕严重AKI。
  • 现有证据不支持常规使用补体阻断治疗CFZ-TMA。

局限性

  • 样本量较小(37例),部分检测(补体活性18例、遗传分析7例)例数有限。
  • 治疗对结局的影响未显示显著性,可能受样本量及非随机治疗分配限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carfilzomib, a new proteasome inhibitor indicated for patients with relapsed/refractory myeloma, has been associated with cases of thrombotic microangiopathy (CFZ-TMA). The role of variants in the complement alternative pathway and therapeutic potential of complement blockade with eculizumab remain to be determined. METHODS: We report 37 cases of CFZ-TMA recorded in the French reference center for TMA with their clinical characteristics, genetic analysis and outcome according to treatments. RESULTS: A trigger was identified in more than half of cases, including eight influenza and five severe acute respiratory syndrome coronavirus-2 cases. All patients presented with acute kidney injury (AKI) [KDIGO stage 3 in 31 (84%) patients] while neurological (n = 13, 36%) and cardiac (n = 7, 19%) damage were less frequent. ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type I repeats-13) and complement activity were normal (n = 28 and 18 patients tested) and no pathogenic variant in the alternative complement pathway was found in 7 patients tested. TMA resolved in most (n = 34, 94%) patients but 12 (44%) still displayed stage 3 AKI at discharge. Nineteen (51%) patients were treated with therapeutic plasma exchange, 14 (38%) patients received corticosteroids and 18 (50%) were treated with eculizumab. However, none of these treatments demonstrated a significant impact on outcomes. CONCLUSION: This study is the largest case series of CFZ-TMA since its approval in 2012. Patients present with severe AKI and experience frequent sequelae. Complement variants and blockade therapy do not seem to play a role in the pathophysiology and prognosis of the disease.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Joseph A, Harel S, Mesnard L, et al. Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes. Nephrol Dial Transplant. 2024. PMID: 38658194. doi:10.1093/ndt/gfae096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。